Ethic Inc. Invests $289,000 in 10x Genomics $TXG

Ethic Inc. acquired a new stake in 10x Genomics (NASDAQ:TXG) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 24,612 shares of the company’s stock, valued at approximately $289,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. GAMMA Investing LLC increased its holdings in 10x Genomics by 81.8% in the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company’s stock valued at $31,000 after purchasing an additional 1,614 shares during the period. Signaturefd LLC increased its holdings in 10x Genomics by 134.3% in the first quarter. Signaturefd LLC now owns 4,203 shares of the company’s stock valued at $37,000 after purchasing an additional 2,409 shares during the period. Whittier Trust Co. acquired a new stake in 10x Genomics in the first quarter valued at $41,000. PNC Financial Services Group Inc. increased its holdings in 10x Genomics by 153.6% in the first quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company’s stock valued at $45,000 after purchasing an additional 3,119 shares during the period. Finally, US Bancorp DE increased its holdings in 10x Genomics by 314.5% in the first quarter. US Bancorp DE now owns 5,973 shares of the company’s stock valued at $52,000 after purchasing an additional 4,532 shares during the period. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on TXG shares. Deutsche Bank Aktiengesellschaft set a $14.00 price objective on 10x Genomics and gave the company a “hold” rating in a report on Friday, August 8th. Wall Street Zen upgraded 10x Genomics from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. Zacks Research upgraded 10x Genomics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. Piper Sandler began coverage on 10x Genomics in a report on Thursday, September 11th. They issued a “neutral” rating and a $15.00 price objective for the company. Finally, UBS Group upped their price target on shares of 10x Genomics from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $13.65.

10x Genomics Trading Down 3.6%

Shares of TXG opened at $12.44 on Friday. The stock has a market capitalization of $1.55 billion, a P/E ratio of -17.77 and a beta of 2.05. The firm’s fifty day simple moving average is $12.85 and its two-hundred day simple moving average is $11.49. 10x Genomics has a 12 month low of $6.78 and a 12 month high of $18.21.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.63. The company had revenue of $172.91 million for the quarter, compared to analysts’ expectations of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The business’s revenue was up 12.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, research analysts predict that 10x Genomics will post -1.43 EPS for the current fiscal year.

Insider Transactions at 10x Genomics

In other news, CEO Serge Saxonov sold 9,348 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $128,908.92. Following the transaction, the chief executive officer owned 945,892 shares of the company’s stock, valued at $13,043,850.68. This represents a 0.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Benjamin J. Hindson sold 7,486 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $103,231.94. Following the transaction, the insider directly owned 440,888 shares in the company, valued at $6,079,845.52. This trade represents a 1.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 39,149 shares of company stock valued at $539,865 in the last 90 days. 9.39% of the stock is currently owned by corporate insiders.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.